Tone mix
Week by week 52 weeks
Share of Alumis Inc. Common Stock's 191 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Oct 5, 2026 · tone +100Alumis Reports Positive Phase 3 Data With Envudeucitinib+105
- Week of Mar 16, 2026 · tone -50Alumis (NASDAQ:ALMS) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS-65
- Week of Jun 1, 2026 · tone +100Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements+64
- Week of Aug 17, 2026 · tone -50Alumis (NASDAQ:ALMS) Cut to "Strong Sell" at Wall Street Zen-62
- Week of May 25, 2026 · tone +100Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements+61
- Week of Aug 11, 2025 · tone -50Alumis Misses Q2 Revenue as Costs Jump | The Motley Fool-50
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Alumis Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 9 | +44 |
| Last 90 sessions | 41 | +6 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 19, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletWAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head Comparison | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletAlumis Inc. (NASDAQ:ALMS) Stock Has Average Price Target of $33.27Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alumis Inc. (NASDAQ:ALMS) Stock Has Average Price Target of $33.27 | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletAlumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock UpPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 9, 2026
3 headlines, average tone +100: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.rttnews.com · 1 outletAlumis Reports Positive Phase 3 Data With EnvudeucitinibPositive
- www.manilatimes.net · 1 outletAlumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresPositive
- www.finanznachrichten.de · 1 outletAlumis Inc.: Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alumis Reports Positive Phase 3 Data With Envudeucitinib | www.rttnews.com | 1 | Positive |
| Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures | www.manilatimes.net | 1 | Positive |
| Alumis Inc.: Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, September 25, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHead to Head Analysis: Pyxis Oncology (NASDAQ:PYXS) and Alumis (NASDAQ:ALMS)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head to Head Analysis: Pyxis Oncology (NASDAQ:PYXS) and Alumis (NASDAQ:ALMS) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Alumis Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.